PYXIS ONCOLOGY
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.
PYXIS ONCOLOGY
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2019-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.pyxisoncology.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
174 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Sitelinks Search Box
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Ridgeback Capital
Ridgeback Capital investment in Series B - Pyxis Oncology
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Pyxis Oncology
Leaps by Bayer
Leaps by Bayer investment in Series B - Pyxis Oncology
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Pyxis Oncology
RA Capital Management
RA Capital Management investment in Series B - Pyxis Oncology
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Pyxis Oncology
Logos Capital
Logos Capital investment in Series B - Pyxis Oncology
RTW Investments LLC
RTW Investments LLC investment in Series B - Pyxis Oncology
Tekla Capital Management
Tekla Capital Management investment in Series B - Pyxis Oncology
BVF Partners
BVF Partners investment in Series B - Pyxis Oncology
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-09 | Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business OfficerIndustry veteran brings expertise in corporate strategy and business development to Pyxis team |
Official Site Inspections
http://www.pyxisoncology.com Semrush global rank: 3.63 M Semrush visits lastest month: 3.92 K
- Host name: pyxis.wpmudev.host
- IP address: 207.246.95.246
- Location: Piscataway United States
- Latitude: 40.5511
- Longitude: -74.4606
- Metro Code: 501
- Timezone: America/New_York
- Postal: 08854
More informations about "Pyxis Oncology"
About Us - Pyxis Oncology
Pyxis Oncology is devoted to transforming the lives of patients with cancer by advancing our innovative and differentiated portfolio of clinical assets that specifically target tumor cells and …See details»
Investor relations | Pyxis Oncology
Nov 11, 2024 Pyxis Oncology is devoted to transforming the lives of patients with cancer by advancing our innovative and differentiated portfolio of biologics that specifically target tumor …See details»
Pyxis Oncology - Crunchbase Company Profile & Funding
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. View contacts for Pyxis Oncology to access new leads and connect with decision-makers.See details»
Pyxis Oncology, Inc. (PYXS) Company Profile & Facts
See the company profile for Pyxis Oncology, Inc. (PYXS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and ...See details»
Pyxis Oncology - LinkedIn
Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression.See details»
Pyxis Oncology - Overview, News & Similar companies - ZoomInfo
May 9, 2024 Pyxis Oncology contact info: Phone number: (617) 453-3596 Website: www.pyxisoncology.com What does Pyxis Oncology do? Founded in 2019, Pyxis Oncology …See details»
Pyxis Oncology Reports Financial Results for the Quarter Ended ...
Sep 30, 2022 Pyxis Oncology, Inc. is an oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for …See details»
Pyxis Oncology Expands Board of Directors with Appointment of …
Mar 13, 2024 "I am delighted to join the Board of Directors at Pyxis Oncology at such a pivotal moment in the Company's journey as they anticipate data readouts for their lead ADC …See details»
Pyxis Oncology Provides Corporate and Financial Update
[email protected] to follow---PYXIS ONCOLOGY, INC. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share data) Years …See details»
Our Approach - Pyxis Oncology
Our ADC generation platform, FACT, developed by Pfizer, equips Pyxis Oncology to potentially develop next-generation ADCs with improved plasma stability, better potency and improved tumor permeability due to optimized payloads, …See details»
Pyxis Oncology Provides Corporate Update and Reports Financial …
May 14, 2024 Pyxis Oncology continues to expand our understanding of PYX-201, and we were excited to share our latest preclinical data at the 2024 American Association for Cancer …See details»
Pyxis Oncology Strengthens Leadership Team with Executive and ...
Jun 8, 2021 Dr. Anthony W. Tolcher is the Chief Executive Officer, Founder and Director of Clinical Research at NEXT Oncology. In 2007, Dr. Tolcher became co-founder of South Texas …See details»
News release - Pyxis Oncology
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for …See details»
Pyxis Oncology Announces Presentations at Upcoming Investor …
May 19, 2022 To learn more about Pyxis Oncology visit www.pyxisoncology.com. Pyxis Oncology Contact: Courtney Dugan Vice President, Head of Investor Relations & Corporate …See details»
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event …
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to …See details»
Pyxis Oncology Closes $152 Million Series B Financing to Further ...
Mar 30, 2021 Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno …See details»
Pyxis Oncology Announces FDA Clearance of Two IND Applications
Dec 1, 2022 FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate Phase 1 clinical trials …See details»
News releases - Pyxis Oncology
Jun 28, 2024 Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose …See details»
Pyxis Oncology
Mar 5, 2024 PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models The PYX-201 target …See details»